 NuCana plc NASDAQ:NCNA today announced that two abstracts describing non-clinical studies related to the mechanisms of action of its proprietary ProTides, Acelarin NUC-1031 and NUC-3373, were selected for poster presentations at the AACR Annual Meeting 2020 on June 22-24, 2020. In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage. 